Clinical trial
A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Subjects With Severe Relapsed or Refractory Autoimmune Diseases (GLEAM)
NCT06294236 is registered in ClinicalTrials.gov with Sana Biotechnology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Subjects With Severe Relapsed or Refractory Autoimmune Diseases (GLEAM)
- Lead sponsor
- Sana Biotechnology
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- April 29, 2024
- Completion date
- March 31, 2028
- Enrollment
- 7 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
anti-neutrophil cytoplasmic antibody-associated vasculitis, granulomatous polyangiitis, lupus erythematosus, microscopic polyangiitis, sle (systemic lupus), systemic lupus erythematosus